Affinage

IL18BP

Interleukin-18-binding protein · UniProt O95998

Audit flag: wrong gene
Length
194 aa
Mass
21.1 kDa
Annotated
2026-06-10
52 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IL-18BP is a secreted high-affinity decoy receptor that neutralizes the pro-inflammatory cytokine IL-18, serving as a key brake on IL-18-driven immune activation (PMID:38455460, PMID:11497494, PMID:31213488). Originally purified from human urine as a 40-residue soluble antagonist distinct from the IL-18Rα/β signaling chains, it forms a 1:1 stoichiometric complex with IL-18 (Kd ~400 pM) with a very slow dissociation rate, sequestering the cytokine and blocking its engagement of the signaling receptor and downstream NF-κB activation (PMID:38455460, PMID:11497494, PMID:30089853). By mass-action, this binding determines the free IL-18 pool: most circulating IL-18 is free in health but largely bound in sepsis (PMID:11497494). IL-18BP expression is transcriptionally induced by IFN-γ through direct STAT1 binding to a proximal GAS element in its promoter, constituting a negative feedback loop, and is co-regulated by C/EBPβ in hepatocytes; this induction is epigenetically gated by CpG methylation adjacent to the GAS element, which restricts IFN-γ responsiveness in monocytes relative to epithelial cells (PMID:19046253, PMID:30089853, PMID:29409936). In vivo, IL-18BP secreted by hepatocytes and macrophages restrains IL-18-driven NK cell cytotoxicity against hepatocytes, and inherited homozygous loss-of-function deletion causes human IL-18BP deficiency with uncontrolled NK-mediated hepatocyte killing (PMID:31213488). The same neutralizing axis acts as a barrier to IL-18 anti-tumor activity and an immune brake during infection: tumors upregulate IL-18BP to limit IL-18 efficacy, and engineered decoy-resistant IL-18 or anti-IL-18BP antibodies that displace pre-bound IL-18 restore T and NK cell activation (PMID:32581358, PMID:36827187, PMID:38592331).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 1999 High

    Established the existence of a soluble, secreted IL-18 antagonist distinct from the membrane IL-18 receptor chains, defining a new mode of IL-18 regulation.

    Evidence IL-18 ligand affinity chromatography from human urine, protein microsequencing, cDNA cloning, and in vitro binding/neutralization

    PMID:11497494 PMID:38455460

    Open questions at the time
    • Did not resolve in vivo physiological role
    • Homology to viral proteins noted but structural basis of binding undefined
  2. 2001 High

    Quantified the IL-18BPa:IL-18 interaction and showed that decoy occupancy controls the free IL-18 pool, distinguishing health from sepsis.

    Evidence Isoform-specific sandwich ELISA, electrochemiluminescence, and mass-action calculations of free vs. bound IL-18

    PMID:11497494

    Open questions at the time
    • Functional role of other isoforms (b, c, d) not established
    • Did not address tissue source of circulating IL-18BP
  3. 2008 High

    Defined the transcriptional mechanism of IL-18BP induction, showing IFN-γ drives expression via direct STAT1 binding to a proximal GAS element, formalizing a negative feedback loop.

    Evidence Promoter mutagenesis, siRNA knockdown, EMSA, and ChIP in DLD-1 colon carcinoma cells

    PMID:19046253

    Open questions at the time
    • IRF-1 independence noted but identity of the required de novo synthesized protein unknown
    • Cell-type generality of GAS dependence not addressed in this study
  4. 2018 High

    Showed expression is epigenetically gated and co-regulated by additional factors, explaining cell-type-specific IFN-γ responsiveness.

    Evidence CpG methylation/demethylation (5-aza), MeCP2 and histone ChIP, RNA-Pol II recruitment (monocytic vs. epithelial); plus STAT1/C/EBPβ reporter, ChIP, and siRNA in hepatic cells

    PMID:29409936 PMID:30089853

    Open questions at the time
    • Mechanism setting differential CpG2 methylation between lineages unknown
    • Interplay of C/EBPβ and STAT1 at the promoter not structurally resolved
  5. 2019 High

    Established IL-18BP as a physiologically essential restraint on IL-18, with human loss-of-function causing uncontrolled NK-mediated hepatocyte killing.

    Evidence Human homozygous deletion genetics and in vitro NK cytotoxicity assays against human hepatocytes

    PMID:31213488

    Open questions at the time
    • Did not establish full spectrum of human disease phenotype
    • Relative contribution of hepatocyte vs. macrophage IL-18BP sources not partitioned
  6. 2020 High

    Demonstrated that the IL-18BP:IL-18 interaction is the mechanistic barrier limiting IL-18 anti-tumor activity, enabling therapeutic decoy-resistant IL-18.

    Evidence Directed evolution of decoy-resistant IL-18 (DR-18) and mouse tumor models with T cell phenotyping

    PMID:32581358

    Open questions at the time
    • Drivers of tumor IL-18BP upregulation not fully defined
    • Did not address normal-tissue toxicity of bypassing the decoy
  7. 2023 High

    Confirmed IL-18BP as an in vivo functional brake on infection-driven lymphoid responses, with engineered antagonists revealing the protective-versus-pathological balance of unleashing IL-18.

    Evidence Mouse T. gondii infection with D2D (decoy-to-the-decoy) and DR-18 treatment, flow cytometry, parasite control readouts

    PMID:36827187

    Open questions at the time
    • Threshold separating beneficial IL-18 release from CD4 T-cell pathology undefined
    • Generalizability across pathogens not established
  8. 2024 High

    Validated pharmacological IL-18BP blockade by antibody that displaces pre-bound IL-18, achieving tumor-localized immune activation without systemic inflammation.

    Evidence Anti-IL-18BP antibody (COM503) in vitro displacement/neutralization and mouse tumor models comparing serum vs. TME cytokines

    PMID:38592331

    Open questions at the time
    • Basis of TME-restricted versus systemic effect not mechanistically resolved
    • Durability and resistance to blockade not addressed
  9. 2025 Medium

    Revealed that loss of IL-18BP restraint paradoxically renders NK cells hypofunctional during infection, framing IL-18BP as required to preserve NK responsiveness.

    Evidence Il18bp knockout mouse, mousepox challenge, NK transfer rescue, viral clearance assays (preprint)

    PMID:bio_10.1101_2025.07.04.663237

    Open questions at the time
    • Preprint, not yet peer-reviewed
    • Molecular basis of IL-18-driven NK exhaustion/hypoactivation undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How IL-18BP structurally engages IL-18 to occlude receptor binding, and how higher-order self-assembly contributes to neutralization in vivo, remain unresolved.
  • Proposed C74 disulfide-mediated tetramer assembly is computational only and unvalidated experimentally
  • No experimental structure of the human IL-18BP self-assembled state confirmed

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4
Localization
GO:0005576 extracellular region 3
Pathway
R-HSA-168256 Immune System 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 2
Partners
IL18

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 IL-18BP was originally discovered by subjecting concentrated human urine to an IL-18 ligand affinity column, purifying a novel 40 amino acid polypeptide. Complete ORF isolation from cDNA libraries revealed a unique soluble antagonist sharing homology with viral proteins, distinct from IL-18Rα and IL-18Rβ chains. It forms a 1:1 high-affinity complex with IL-18 (Kd=400 pM) with a very low dissociation rate. IL-18 ligand affinity chromatography, protein microsequencing, cDNA library screening, in vitro binding/neutralization assays Immune network High 11497494 38455460
2001 IL-18BP (isoform a) forms a 1:1 stoichiometric high-affinity complex with IL-18 (Kd=400 pM) with a very low dissociation rate, effectively blocking IL-18 bioactivity. A sandwich ELISA specific to IL-18BPa was developed and validated, showing no cross-reactivity with IL-18 or other IL-18BP isoforms (b, c, d). Using mass-action calculations, most circulating IL-18 in healthy individuals (~85%) is free, whereas in sepsis, the majority is bound to IL-18BPa. Sandwich ELISA, electrochemiluminescence assay, mass-action law calculations Cytokine High 11497494
2008 IFN-γ induces IL-18BP expression in DLD-1 colon carcinoma cells via direct binding of STAT1 to a proximal gamma-activated sequence (GAS) element in the IL-18BP promoter. Mutational analysis showed this proximal GAS is pivotal; siRNA knockdown confirmed essential role of STAT1; EMSA and chromatin immunoprecipitation (ChIP) proved STAT1 binding to this specific GAS site. Maximal expression required de novo protein synthesis but was independent of IRF-1. Promoter mutational analysis, siRNA knockdown, EMSA, chromatin immunoprecipitation (ChIP) Journal of cellular and molecular medicine High 19046253
2018 Remifentanil upregulates hepatic IL-18BP expression at the transcriptional level via activation of STAT1 and C/EBPβ transcription factors. Actinomycin D abolished remifentanil-induced IL-18BP mRNA upregulation; luciferase reporter assay confirmed increased IL-18BP promoter transcription; Western blot and ChIP assays showed STAT1 and C/EBPβ activation and binding; silencing of either STAT1 or C/EBPβ blocked IL-18BP upregulation. The induced IL-18BP was functionally active, inhibiting IL-18-activated NF-κB phosphorylation. Actinomycin D inhibition, luciferase reporter assay, ChIP, Western blot, siRNA knockdown Laboratory investigation High 30089853
2018 Epigenetic regulation by CpG methylation at a specific CpG site (CpG2) neighboring the γ-activated sequence (GAS) in the IL18BP promoter determines differential IFNγ-induced IL-18BP expression between monocytic and epithelial cells. CpG2 is constitutively methylated in monocytic but unmethylated in epithelial cells. 5-aza-2'-deoxycytidine (DNA demethylation) enhanced IFNγ-induced IL-18BP only in monocytic cells; demethylation impeded MeCP2 binding to CpG2, increased adjacent H3K9-acetylation, and enhanced RNA-polymerase-II recruitment to the IL18BP transcriptional start. 5-aza-2'-deoxycytidine treatment, ChIP for MeCP2 and histone modifications, RNA-polymerase-II recruitment analysis, promoter CpG methylation analysis Biochimica et biophysica acta. Gene regulatory mechanisms High 29409936
2019 Inherited homozygous loss-of-function deletion in IL18BP causes IL-18BP deficiency in humans. In the absence of IL-18BP, excessive NK cell activation by IL-18 results in uncontrolled killing of human hepatocytes in vitro. Human IL-18 and IL-18BP are both secreted primarily by hepatocytes and macrophages in the liver. This establishes IL-18BP as an essential restraint on IL-18-driven NK cell cytotoxicity in the liver. Human genetic analysis (homozygous deletion), in vitro NK cell cytotoxicity assay with human hepatocytes, IL-18BP knockout functional studies The Journal of experimental medicine High 31213488
2020 IL-18BP is a high-affinity decoy receptor that is frequently upregulated in diverse human and mouse tumors and limits anti-tumor activity of IL-18 in vivo. Directed evolution was used to engineer 'decoy-resistant' IL-18 (DR-18) that maintains receptor signaling but is impervious to IL-18BP inhibition, demonstrating that the IL-18BP:IL-18 interaction is the mechanistic barrier to IL-18 anti-tumor efficacy. Directed evolution/protein engineering, mouse tumor models, flow cytometry for T cell phenotyping Nature High 32581358
2007 In human monocytic THP-1 cells stimulated with P. gingivalis LPS, both IL-18 and IL-18BPa are secreted. Addition of antibodies to IL-18BPa to stimulated cultures resulted in increased levels of free IL-18, directly demonstrating a specific neutralizing interaction between IL-18 and IL-18BPa in this cellular system. VIP (10⁻⁸M) inhibited both IL-18 and IL-18BPa secretion. ELISA, neutralizing antibody competition assay in THP-1 cell cultures Journal of dental research Medium 17720860
2003 IL-18BPa:Fc significantly inhibited LPS/IL-12-induced IFN-γ and MMP-9 release from human whole blood cultures, demonstrating functional IL-18 blockade in a physiologically relevant ex vivo system. IL-18BPa:Fc cooperated additively with immunosuppressive drugs (dexamethasone, mycophenolic acid) to further reduce IFN-γ production. Human whole blood ex vivo culture, ELISA for IFN-γ and MMP-9 Biochemical pharmacology Medium 12907250
2003 A mouse monoclonal antibody (2A6H11) specific for rat IL-18BP was generated. Its binding epitope was mapped to amino acids 29-60 on IL-18BP. Critically, this antibody does not interfere with IL-18BP function (i.e., does not block IL-18 binding). Monoclonal antibody generation, epitope mapping, functional ELISA Immunology letters Medium 12505199
2003 LPS treatment of rats selectively upregulates IL-18BP mRNA in the liver (~12-fold above naive levels, peaking at 3h), whereas IL-18 mRNA expression in the liver was unaffected by LPS. This differential regulation suggests an endogenous feedback mechanism for controlling IL-18 activity during inflammatory responses. Real-time PCR of rat liver tissue after peripheral LPS injection Cytokine Medium 12788303
2016 Bioinformatics analysis across 86 mammalian species shows IL-18BP is consistently most similar to IL-1R9 (IL-1R accessory protein-like 2). IL-1R9 and IL-1R8 share conserved amino acid sequences homologous to binding site A of human and viral IL-18BPs, conserved intron/exon boundaries, and protein structure, suggesting evolutionary relationship and potential IL-18 binding capacity. Bioinformatics/phylogenetic analysis of Ensembl and NCBI databases, protein structure comparison Journal of immunology Low 27881706
2023 MD simulation analysis of all known IL-18–IL-18BP PDB crystal structures revealed that residues 68–81 of IL-18 adopt a disordered conformation in all IL-18–IL-18BP complexes but a 310-helical structure in IL-18–receptor complexes. C74 within this epitope can form an intermolecular disulfide bond in the human tetrameric IL-18–IL-18BP assembly. Simulations show the helical form of this epitope stabilizes the heterodimer by reducing backbone flexibility, and the exposed C74 sidechain in disordered form mediates self-assembly of IL-18–IL-18BP dimers. All-atom molecular dynamics simulations of PDB structures and computed models Computational and structural biotechnology journal Low 37484491
2022 In rainbow trout, recombinant IL-18BP (rIL-18BP) significantly downregulates NF-κB activity induced by IL-18 via its receptor complex (IL-18Rα + IL-18Rβ) in HEK293T cells, demonstrating conserved decoy receptor function. Co-IP assays showed IL-18Rβ forms a complex with MyD88, IRAK4, IRAK1, TRAF6, and TAB2, indicating IL-18Rβ is the signaling-competent subunit recruiting these downstream molecules. NF-κB reporter assay in HEK293T cells with chimeric receptor transfection, Co-immunoprecipitation Developmental and comparative immunology Medium 36496012
2023 In Toxoplasma gondii infection, IFN-γ produced during infection induces high levels of IL-18BP, which restrains IL-18-mediated ILC and T cell responses. Antagonism of IL-18BP with a 'decoy-to-the-decoy' (D2D) construct (non-signaling IL-18 that sequesters IL-18BP) enhanced innate lymphoid cell and T cell responses and improved parasite control, establishing IL-18BP as a functional brake on IL-18 activity in vivo. DR-18 (IL-18 resistant to IL-18BP) promoted CD4+ T cell IFN-γ but also caused CD4+ T cell-mediated pathology. Mouse infection model with T. gondii, D2D and DR-18 protein treatment, flow cytometry for immune cell responses Cell reports High 36827187
2024 An anti-IL-18BP monoclonal antibody (COM503) was generated that blocks the IL-18BP:IL-18 interaction and displaces pre-complexed IL-18 from IL-18BP, thereby restoring free IL-18 activity and enhancing T and NK cell activation in vitro. In vivo, a surrogate anti-IL-18BP antibody caused pronounced tumor microenvironment-localized immune modulation (increased polyfunctional non-exhausted T and NK cells) without systemic inflammatory cytokine elevation, establishing IL-18BP blockade as a mechanism for TME-specific IL-18 release. Anti-IL-18BP antibody generation, in vitro displacement/neutralization assay, mouse tumor models, cytokine measurement in serum vs. TME Cancer immunology research High 38592331
2019 miR-92b-5p directly suppresses IL-18BP expression in microglia. Transfection of miR-92b-5p into activated microglia significantly decreased IL-18BP expression while increasing IL-18 mRNA; miR-92b-5p inhibitor reversed this effect. After spinal cord injury, miR-92b-5p is upregulated in the injured cord, correlating with decreased IL-18BP and increased IL-18 expression. miRNA transfection in primary microglia, qRT-PCR, intrathecal injection of miR-92b-5p inhibitor in mouse SCI model European review for medical and pharmacological sciences Medium 30915731
2025 In an IL-18bp knockout mouse model, excess IL-18 activity (without IL-18BP restraint) caused NK cells to be inert/hypofunctional upon mousepox infection despite being hyperactivated at rest. IL-18bp KO mice succumbed to viremic MAS-like disease with poor virus-specific CTL expansion, establishing that IL-18BP is required to maintain NK cell responsiveness to infectious challenge by preventing IL-18-driven NK hypoactivation. Il18bp knockout mouse model, mousepox infection challenge, NK cell transfer rescue experiments, flow cytometry, viral clearance assays bioRxivpreprint Medium bio_10.1101_2025.07.04.663237

Source papers

Stage 0 corpus · 52 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 300 32581358
2018 Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the rheumatic diseases 235 29472362
2001 A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 223 11497494
2014 Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. Journal of leukocyte biology 145 25548255
2019 Inherited IL-18BP deficiency in human fulminant viral hepatitis. The Journal of experimental medicine 93 31213488
2014 Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators of inflammation 88 24733959
2010 Serum IL-18 and IL-18BP levels in patients with Chikungunya virus infection. Viral immunology 48 20121409
2009 Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis. Clinical and experimental medicine 43 19225717
2014 Pressure overload induces IL-18 and IL-18R expression, but markedly suppresses IL-18BP expression in a rabbit model. IL-18 potentiates TNF-α-induced cardiomyocyte death. Journal of molecular and cellular cardiology 42 25108227
2023 Interleukin-18 and IL-18BP in inflammatory dermatological diseases. Frontiers in immunology 41 36742296
2007 Free Interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men. Arteriosclerosis, thrombosis, and vascular biology 32 17951325
2012 Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. Journal of neuroinflammation 29 22913567
2020 IL-18 binding protein (IL-18BP) as a novel radiation countermeasure after radiation exposure in mice. Scientific reports 28 33122671
2024 IL-18 and IL-18BP: A Unique Dyad in Health and Disease. International journal of molecular sciences 26 39769266
2020 Interleukin 18 (IL-18) and its binding protein (IL-18BP) are increased in patients with epilepsy suggesting low-grade systemic inflammation. Seizure 26 32659652
2008 Molecular mechanisms of IL-18BP regulation in DLD-1 cells: pivotal direct action of the STAT1/GAS axis on the promoter level. Journal of cellular and molecular medicine 26 19046253
2019 MiR-92b-5p inhibitor suppresses IL-18 mediated inflammatory amplification after spinal cord injury via IL-18BP up-regulation. European review for medical and pharmacological sciences 24 30915731
2003 IL-18BPa:Fc cooperates with immunosuppressive drugs in human whole blood. Biochemical pharmacology 23 12907250
2008 Interleukin 18 binding protein (IL18-BP) inhibits neointimal hyperplasia after balloon injury in an atherosclerotic rabbit model. Journal of vascular surgery 22 18455646
2023 Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. mAbs 21 37469014
2024 Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects. Cancer immunology research 20 38592331
2017 Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjögren's syndrome. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20 28057714
2007 VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. Journal of dental research 18 17720860
2016 Circulating IL-18 Binding Protein (IL-18BP) and IL-18 as Dual Biomarkers of Total-Body Irradiation in Mice. Radiation research 17 27023262
2023 IL-18BP mediates the balance between protective and pathological immune responses to Toxoplasma gondii. Cell reports 16 36827187
2014 Effect of hydrodynamics-based delivery of IL-18BP fusion gene on rat experimental autoimmune myocarditis. Clinical and experimental medicine 15 24122347
2015 The effects of IL-18BP on mRNA expression of inflammatory cytokines and apoptotic genes in renal injury induced by infrarenal aortic occlusion. The Journal of surgical research 14 27083945
2017 Enhanced Expression of IL-18 and IL-18BP in Plasma of Patients with Eczema: Altered Expression of IL-18BP and IL-18 Receptor on Mast Cells. Mediators of inflammation 13 28839348
2025 Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models. Molecular therapy : the journal of the American Society of Gene Therapy 10 40676834
2022 IL-18BP Alleviates Anxiety-Like Behavior Induced by Traumatic Stress via Inhibition of the IL-18R-NLRP3 Signaling Pathway in a Mouse Model of Hemorrhagic Shock and Resuscitation. Molecular neurobiology 10 36269543
2023 Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation. Cytokine 8 37918054
2018 Remifentanil upregulates hepatic IL-18 binding protein (IL-18BP) expression through transcriptional control. Laboratory investigation; a journal of technical methods and pathology 8 30089853
2016 IL1R9 Is Evolutionarily Related to IL18BP and May Function as an IL-18 Receptor. Journal of immunology (Baltimore, Md. : 1950) 8 27881706
2018 Epigenetic regulation by CpG methylation splits strong from retarded IFNγ-induced IL-18BP in epithelial versus monocytic cells. Biochimica et biophysica acta. Gene regulatory mechanisms 7 29409936
2003 A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP. Immunology letters 7 12505199
2022 Functional characterization of IL-18 receptor subunits, IL-18Rα and IL-18Rβ, and its natural inhibitor, IL-18 binding protein (IL-18BP) in rainbow trout Oncorhynchus mykiss. Developmental and comparative immunology 6 36496012
2003 Up-regulation of IL-18BP, but not IL-18 mRNA in rat liver by LPS. Cytokine 6 12788303
2024 Interleukin-18 Binding Protein (IL-18BP): A Long Journey From Discovery to Clinical Application. Immune network 5 38455460
2023 Detection of Free Bioactive IL-18 and IL-18BP in Inflammatory Disorders. Methods in molecular biology (Clifton, N.J.) 5 37355553
2022 IL-18BP Improves Early Graft Function and Survival in Lewis-Brown Norway Rat Orthotopic Liver Transplantation Model. Biomolecules 4 36551229
2024 IL-18BP Therapy Ameliorates Reproductive and Metabolic Phenotypes in a PCOS Mouse Model by Relieving Inflammation, Fibrosis and Endoplasmic Reticulum Stress. Reproductive sciences (Thousand Oaks, Calif.) 3 38977641
2024 IL-18 signaling is regulated by caspase 6/8 and IL-18BP in turbot (Scophthalmus maximus). International journal of biological macromolecules 3 39181350
2023 Disruption of IL-18 signaling via engineered IL-18BP biologics alleviates experimental cholestatic liver disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 3 37774670
2023 A small non-interface surface epitope in human IL18 mediates the dynamics and self-assembly of IL18-IL18BP heterodimers. Computational and structural biotechnology journal 2 37484491
2025 Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential. Cytokine 1 40544635
2019 No IL-18BP? Avoid HAV. The Journal of experimental medicine 1 31243052
2011 [The study of IL-18 and IL-18BP balance in aplastic anemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 1 22339918
2010 Plasma IL-18 and IL-18BP are altered differently in reverse remodeling following aortic valve replacement. Scandinavian cardiovascular journal : SCJ 1 19961286
2025 Engineered Probiotics Secreting IL-18BP and Armed with Dual Single-Atom Catalysts for Synergistic Therapy in Ulcerative Colitis. ACS applied materials & interfaces 0 40890100
2025 The role of IL-18BP in alleviating anxiety-like behaviors after traumatic brain injury in rats by modulating astrocytic pyroptosis in amygdala. Brain injury 0 40995942
2024 Blood Interleukin-18 (IL-18) and IL-18 Binding Protein (IL-18BP) Levels Following Midline Laparotomy: A Prospective Randomized Study of Patients With Benign Disease and Patients With Cancer. Anticancer research 0 38677734
2013 [Effect of IL-18BP on Fractalkine chemokine expression in the kidney tissue of rats with renal fibrosis]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 0 24342215

Missed literature

Know a paper Affinage missed for IL18BP? Flag it for the maintainers and the community.

No submissions yet.